Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

GW Pharmaceuticals plc provides update on Cannabinoid Pipeline


Monday, 17 Mar 2014 03:00am EDT 

GW Pharmaceuticals plc:Completes Phase 1 clinical trial of GWP42006 to treat epilepsy.GWP42006 is product which features non-psychoactive cannabinoid cannabidivarin (CBDV) extracted from cannabis plant.CBDV was well tolerated even at highest tested dose and no significant side effects were observed.There were no serious or severe adverse events, nor any withdrawals due to adverse events, and all mild adverse events resolved on treatment.GW expects to commence a Phase 2 study of CBDV in patients with epilepsy later in 2014, using doses identified as appropriate in this Phase 1 study.Intellectual Property Office in United Kingdom has granted patent for use of CBDV in treatment of epilepsy.Commences 12-week randomized, double blind, placebo controlled Phase 2b study of GWP42004 to treat Type 2 diabetes.GWP42004 is orally administered product which features plant-derived tetrahydrocannabivarin (THCV) as active ingredient.Study is expected to enroll about 200 patients with estimated completion date of second half of 2015.Commences Phase 2a trial using GWP42003 to treat schizophrenia.GWP42003 featured purified CBD as active ingredient.Study is expected to enroll about 80 patients with estimated completion date of second half of 2015. 

Company Quote

435.75
-4.5 -1.02%
12:12pm EDT